Veracyte, Inc.
VCYT
$28.61
-$0.46-1.58%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.75% | 18.20% | 20.81% | 28.58% | 26.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.75% | 18.20% | 20.81% | 28.58% | 26.69% |
| Cost of Revenue | 12.27% | 2.92% | 26.18% | 22.90% | 13.20% |
| Gross Profit | 14.37% | 25.56% | 18.51% | 31.09% | 33.29% |
| SG&A Expenses | 6.29% | 6.26% | 3.83% | 18.87% | 8.47% |
| Depreciation & Amortization | -13.25% | -12.21% | -20.91% | -28.86% | -29.04% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.32% | 5.30% | 9.09% | 19.22% | 10.77% |
| Operating Income | 161.98% | 290.67% | 334.38% | 286.02% | 167.85% |
| Income Before Tax | -83.02% | 489.31% | 111.30% | 156.59% | 188.93% |
| Income Tax Expenses | 37.06% | 965.91% | 23.36% | 1,199.35% | 1,201.60% |
| Earnings from Continuing Operations | -117.09% | 478.06% | 118.07% | 151.17% | 168.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -117.09% | 478.06% | 118.07% | 151.17% | 168.25% |
| EBIT | 161.98% | 290.67% | 334.38% | 286.02% | 167.85% |
| EBITDA | 76.78% | 880.41% | 372.60% | 72.45% | 1,039.68% |
| EPS Basic | -116.69% | 462.65% | 117.03% | 148.38% | 164.62% |
| Normalized Basic EPS | 147.54% | 918.70% | 298.61% | 214.09% | 193.98% |
| EPS Diluted | -117.86% | 461.45% | 115.84% | 146.34% | 158.33% |
| Normalized Diluted EPS | 149.40% | 898.37% | 286.81% | 208.41% | 193.28% |
| Average Basic Shares Outstanding | 2.42% | 4.37% | 6.16% | 5.78% | 5.60% |
| Average Diluted Shares Outstanding | 1.59% | 7.08% | 9.30% | 7.77% | 6.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |